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Edited by Thomas L. JamesAbstract The botulinum neurotoxin A C-terminal fragment
(Hc), which mediates the binding of the toxin to neuronal cell
surface receptors, comprises two subdomains, Hc-N (amino
acids 873–1095) and Hc-C (amino acids 1096–1296). In order to
deﬁne the minimal fragment of Hc carrying protective antigenic
properties, Hc, Hc-N and Hc-C have been produced as
recombinant proteins in Escherichia coli, and have been tested
for their antigenicity in mouse protection assays. Hc, Hc-N and
Hc-C induced similar antibody levels as shown by ELISA.
However, a single immunization with Hc (10 lg) fully protected
mice challenged with 103 mouse lethal dose 50 of toxin, whereas
Hc-N, Hc-C, or Hc-N plus Hc-C did not give any protection.
Triple immunizations with Hc-N or Hc-C were necessary to
induce a higher level of protection. Circular dichroism and
ﬂuorescence studies showed that the isolated subdomains were
folded and stable. However, an intense near-UV dichroic signal
was only observed in the Hc spectrum, revealing a highly
structured interface between both subdomains. Taken together,
the results show that the generation of protective antibodies
requires the whole Hc domain and especially the native structure
of the interfacial region between Hc-N and Hc-C.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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doi:10.1016/j.febslet.2004.06.094compounds. It is responsible for severe food intoxication in
humans and animals, called botulism. Based on its high level of
activity, BoNT/A is considered as a potential weapon. In ad-
dition, BoNT/A is also a therapeutic agent, which is used in the
treatment of numerous dystonias [1,2]. BoNT/A is produced as
a single chain protein, which is poorly active, and it is pro-
teolytically cleaved in an active di-chain form constituted of a
light (about 50 kDa) and a heavy (about 100 kDa) chain linked
by a disulﬁde bridge. The C-terminal half of the heavy chain,
named fragment C (Hc), recognizes a surface receptor on
neurons, which provokes the internalization of the whole toxin
into endocytic vesicles. The N-terminal half of the heavy chain
mediates the translocation of the light chain, which is the in-
tracellular active domain, into the cytoplasm of the neuron. In
the motor nerve ends and autonomic cholinergic junctions,
BoNT/A cleaves SNAP25, which is one of the three SNARE
proteins having a determinant role in neuroexocytosis.
Therefore, BoNT/A blocks the Ca2þ induced release of ace-
tylcholine and causes ﬂaccid paralysis [3–5]. The crystal
structure of BoNT/A has been solved and the functional do-
mains correspond to distinct structures [6]. Hc (residues 873–
1296) remains isolated from the rest of the molecule and
comprises two subdomains corresponding to amino acids 873–
1095 (Hc-N) and amino acids 1096–1296 (Hc-C). Hc-N and
Hc-C are b-strand rich structures of almost identical sizes. Hc-
N has two seven-stranded b-sheets, while Hc-C adopts a
modiﬁed b-trefoil with a b-hairpin capping the base of the
domain (Fig. 1). The two subdomains have possibly evolved
from an ancestral binding domain [6,7]. The precise role of Hc-
N and Hc-C in the binding to the cell surface receptor, which
could involve a ganglioside and a membrane protein, has not
been fully determined (review [5]).
Prevention of botulism can be eﬃciently achieved by vacci-
nation, which generates neutralizing antibodies against
botulinum neurotoxin. Botulinum vaccines are basically for-
malin-inactivated culture supernatants from Clostridium bot-
ulinum grown in fermentor or puriﬁed neurotoxin. This
includes large-scale production of highly toxic material and
inactivation by formaldehyde. To reduce the cost and increase
safety conditions, subunit vaccines based on immunogenic
non-toxic fragments of the neurotoxin have been developed.
Such attempt has been ﬁrst performed with tetanus toxin.blished by Elsevier B.V. All rights reserved.
Fig. 1. Structure of the BoNT/A receptor binding domain (Hc) and the
two subdomains Hc-N and Hc-C according to [6]. The ﬁve Trps lo-
cated at the interface of the two subdomains are shown in red. The
brackets indicate the interfacial region (IR). Residues 873, 1096 and
1296 label the termini residues of each subdomains.
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protect mouse challenged with active tetanus toxin [8]. Similar
strategy was used with BoNT/A [9] and a new generation of
botulinum vaccines has been designed on the basis of re-
combinant Hc of the various BoNT types [10]. Moreover,
neutralizing antibodies constitute the only speciﬁc treatment of
botulism. Monoclonal antibodies and Fab fragments from
animal polyclonal antibodies are more appropriate than se-
rotherapy for a safe treatment. However, numerous attempts
to produce high-aﬃnity neutralizing monoclonal antibodies by
immunizing mice with detoxiﬁed BoNT have been unsuccess-
ful. Since Hc from BoNT/A elicits neutralizing antibodies [9],
this domain has been used as immunogen and has permitted to
generate mouse neutralizing monoclonal antibodies [11,12].
Therefore, recombinant immunogenic BoNT Hc domain
proves to be an eﬃcient antigen to generate neutralizing an-
tibodies for immunotherapy and also an appropriate vaccine
candidate. Since the Hc domain of BoNT/A contains two
subdomains, we have investigated the potency of each sub-
domain to induce a protective response in mice, in order to
deﬁne the minimal fragment of Hc carrying protective anti-
genic properties.2. Materials and methods
2.1. Plasmids, production and puriﬁcation of recombinant proteins
DNAs coding for Hc, Hc-N and Hc-C were PCR ampliﬁed from C.
botulinum NCTC2916 whole DNA with primers P5 (50-GGATC-
CAATATTATTAATACTTCTATATTGAATTT- AAG-30) and P729
(50-GTCGACTTACAGTGGCCTTTC- TCCCCA-30) for Hc, P5 and
P747, (50-GTCGACCTGAATTTGATTGATTATCATATAAATC-
30) for Hc-N, and P748 (50-GAATTCATTTTAAAAGACTTT-
TGGGGTGAT- TATTTAC-30) and P729 for Hc-C. The primers add
a BamHI site at the 50 part and a SalI site at the 30 part of the DNAs
coding Hc and Hc-N, and EcoRI and SalI sites for the DNA coding
Hc-C. Ampliﬁed DNAs were cloned into pET28b (Novagen) and the
recombinant plasmids were transformed into Escherichia coli strain
BL21. DNA constructs were checked by DNA sequencing. The re-
combinant strains were grown in LB medium supplemented with
kanamycin (50 lg/mL), at 25 C until OD 0.8, induced with isopropyl-
1-thio-b-D-galactopyranoside (0.5 mM IPTG) and grown at 25 C for
an additional 20 h. The bacterial cells were collected by centrifugation,suspended in 50 mM NaH2PO4, pH 8, 300 mM NaCl, and lyzed by
sonication. The lysates were centrifuged and ﬁltered on a 0.45 lm ﬁlter,
and the six His-tag fusion proteins were puriﬁed on a cobalt column
(Clontech) according to the recommendations of the manufacturer.
Elution was done with 150 mM imidazole in the same buﬀer. Puriﬁed
proteins were analyzed by 10% SDS–polyacrylamide gel electropho-
resis (PAGE). For spectroscopy studies, the recombinant proteins were
desalted on a Sephadex G-25 Superﬁne Hitrap desalting column
(Amersham Biosciences) against 5 mM sodium phosphate, pH 7.4.
2.2. Circular dichroism (CD) spectroscopy
The measurements were done at 22 and 37 C with constant N2
ﬂushing as described previously [13,14]. Far-UV and near-UV CD
spectra were measured in 1 and 10 mm path length quartz cells, re-
spectively. The protein concentrations were greater than 10 lM (1 mL)
for near-UV CD and ranging from 2 to 5 lM (200 lL) for far-UV
acquisitions. The scans were recorded using a bandwidth of 2 nm and
an integration time of 1 s at a scan rate of 0.5 nm/s. Each spectrum
represents the average of 20 scans. Whatever the UV region investi-
gated, the blank was 5 mM sodium phosphate, pH 7.4. The spectra
were corrected for blank and then, a smoothing algorithm was applied
with the minimum ﬁlter in the CD6 software (CDMax, ﬁlter 5). The
mean residue ellipticity in far-UV, ½hF and the molar ellipticity in
near-UV, ½hN were, respectively, calculated from the relations½hF ¼ ð100 hmÞ=ðC  l NÞ and ½hN ¼ ð100 hmÞ=ðC  lÞ, where
hm is the measured ellipticity in degrees, C is the concentration in mole
per liter, l is the path length of the cell in centimeter and N is the
number of residues. The value 100 arises from the conversion of
the concentration in mole per liter to decimole per cubic centimeter.
The units of the mean residue ellipticity ½hF and that of the molar
ellipticity ½hN are expressed in degrees square centimeter per decimole
residue (deg cm2/dmol res) and in degrees square centimeter per deci-
mole (deg cm2/dmol), respectively. The spectra acquired in the region
ranging from 220 to 260 nm are reported in molar ellipticity ½hN, since
we attribute these bands to tertiary constraints on aromatic residues
(see the main text for details).
2.3. Fluorescence spectroscopy
Fluorescence measurements were performed with a FP-750 spec-
troﬂuorimeter (Jasco, Tokyo, Japan) in a thermostated cell holder
using a 1 cm path length quartz cell with constant stirring. The tem-
perature of the samples was regulated by a thermostated bath and
monitored using a digital thermometer. Bandwidths of 5 nm were used
for both excitation and emission beams. The excitation wavelength was
ﬁxed at 295 nm where the contribution of tyrosine residues is negli-
gible. The emission spectra were recorded from 300 to 400 nm at a scan
rate of 60 nm/min. The proteins were diluted to 1 lM in 2 mL of 5 mM
sodium phosphate, pH 7.4. Spectra were recorded 10 min after the
sample had reached the target temperature. For each temperature
studied, the protein spectra were corrected for blank and the maximal
emission wavelength (kmax) was calculated from the average of at least
four measured emission spectra.
2.4. Mouse protection assays
Swissmalemice (20–25 g) were injected intraperitoneally with 10 lg of
recombinant proteinhomogenized in 1mgaluminumhydroxide (Alugel,
Serva) as indicated. Two weeks after the ﬁnal immunization, blood
samples were taken for ELISA titration and the mice were challenged
with 103 mouse lethal dose (MLD)50 of BoNT/A per mouse.
2.5. Rabbit immunizations
New Zealand female rabbits (about 3 kg) were injected in foot pads
with 100 lg recombinant protein in 1 mL PBS homogenized with 1 mL
Freund’s complete adjuvant for the ﬁrst immunization and then Fre-
und’s incomplete adjuvant for the following injections (4 and 6 weeks
after the initial immunization). Blood samples were collected 10 days
after the last injection.
2.6. Immunoblotting analysis
Recombinant proteins (1 lg) were separated by SDS–PAGE and
transferred to a nitrocellulose membrane (Hybond-C, Amersham). The
membranes were blocked with 5% skimmed milk in PBS and were
incubated with rabbit antibodies (1/100 000) against Hc, Hc-N or Hc-C
for 1 h at room temperature. The blots were then treated with horse-
Fig. 2. SDS–PAGE and Coomassie blue staining of the recombinant proteins Hc, Hc-N and Hc-C (5 lg protein in each well) (A), and Western
blotting with rabbit antiserum against whole Hc (B), Hc-N (C) and Hc-C (D). For Western blotting, 1 lg of recombinant protein was electro-
phoresed, transferred to nitrocellulose, and bound antibodies were visualized with horseradish peroxidase protein A and ECL kit.
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M. Tavallaie et al. / FEBS Letters 572 (2004) 299–306 301radish peroxidase-conjugated protein A (Bio-Rad) and analyzed with
the enhanced chemiluminescence system (ECL, Amersham Pharmacia
Biotech).
2.7. ELISA
Polyvinylchloride 96-well plates (Falcon) were coated with Hc (1 lg/
mL in 15 mM Na2CO3, 36 mM NaHCO3, pH 9.8, 100 lL/well)
overnight at 4 C and were blocked with PBS containing 0.1% gelatin
(1 h, room temperature). The plates were washed four times with PBS
containing 0.1% Tween 20 (Sigma) (PBST) and serial twofold dilutions
in PBST starting at 1:200 of mouse serum samples were then added
(100 lL/well). The plates were incubated 3 h at 37 C and washed four
times. Peroxidase anti-mouse immunoglobulin conjugate (Amersham
Biotech; 1:2000; 100 lL/well) was added and the plates were incubated
1 h at 37 C and washed. For IgG and IgM assays, peroxidase anti-
mouse IgG and IgM immunoglobulins (Sigma A4416 and A8786) were
used at 1:5000 and 1:200 dilution, respectively. The revelation was
done with orthophenylenediamine (OPD, Sigma) and H2O2 and the
reaction was stopped with 3 M HCl (50 lL/well). The plates were read
with a microplate reader (490 nm).
2.8. Neutralizing antibodies
Neutralizing antibodies against BoNT/A were determined by the
mouse test. Mixtures of serial dilutions of sera in phosphate buﬀer (50
mM Na2HPO4, pH 6.5) containing 1% gelatin with BoNT/A (10
MLD) in 1 mL ﬁnal volume were incubated 30 min at room temper-
ature and injected intraperitoneally in 20–22 g Swiss mice. The mice
were observed for death until a period of 4 days. Results were ex-
pressed as inverses of the highest serum dilutions, which neutralize 10
MLD of BoNT/A.Wavelength, nm Wavelength, nm
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Fig. 3. CD spectra of the recombinant proteins in the far-UV (A),
between 220 and 260 nm (B) and in the near-UV (C). Hc (bold line),
Hc-N (thin line) and Hc-C (dotted line). In (D), the near-UV CD
spectrum of Hc (bold line) is compared with the sum of the near-UV
CD spectra of Hc-N and Hc-C (thin line). The diﬀerence between the
two signals is shown as a dotted line.3. Results
3.1. Recombinant Hc, Hc-N and Hc-C
Production and puriﬁcation of the recombinant domains of
BoNT/A were performed as described in Section 2. We found
that the production of Hc and the two subdomains Hc-N and
Hc-C in fusion with a six His-tag provided by the vector
pET28 was increased when the recombinant strains were
grown at low temperature (25 C) and induced with a low
concentration of IPTG (0.5 mM). The yields of production
were approximately 10 mg of puriﬁed protein per liter of cul-
ture. The recombinant proteins were mostly recovered in the
soluble fraction of the lysates and were puriﬁed on metal
aﬃnity columns. As shown in Fig. 2, puriﬁed Hc, Hc-N and
Hc-C migrated at the expected size and were recognized by
polyclonal antibodies raised against the whole Hc domain.
Cross immunogenicity between the two subdomains was
tested by immunoblotting with rabbit serum raised againstHc-N and Hc-C. Antibodies against Hc-N or Hc-C recognized
the corresponding recombinant proteins, respectively, and no
cross-reaction was observed between the two subdomains
(Fig. 2). Antibodies against Hc-C detected in addition to Hc-C
migrating at the expected size, a 60 kDa band, which probably
corresponded to partial protein aggregation.
3.2. Circular dichroism and ﬂuorescence analysis
Fig. 3A shows the far-UV CD spectra of the three proteins.
A positive band at 195 nm and a broad negative signal from
210 to 220 nm characterize the spectrum in the far-UV region
of the isolated Hc-N fragment. These features correspond to a
Table 1
Maximal emission wavelengths and intensities of tryptophan intrinsic
ﬂorescence (e.g. 295 nm) of Hc, Hc-N and Hc-C at 20 C
Hc Hc-N Hc-C
kmax (nm) 341 341 344
Fluorescence intensity (a.u.) 303 89 83
340
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Fig. 4. Thermal denaturation of the proteins. Maximal wavelength
emission values of the recombinant proteins Hc (diamonds), Hc-N
(squares) and Hc-C (triangle) as a function of temperature.
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N was folded and its secondary structure content agreed with
the X-ray structure of Hc-N within the whole domain, com-
posed of 14 b-strands organized in two b-sheets and one a-
helix [6] (Fig. 1). The absence of the negative band at 222 nm,
characteristic of a-structures, can be ascribed to the low a-helix
content (7%) found in the Hc-N subdomain.
The CD spectra of Hc and Hc-C showed a negative signal at
195 nm, a relatively weak positive band around 204 nm and a
wide negative band between 210 and 220 nm characteristic of
b-structures. The strong negative signal at 195 nm found in
Hc-C suggests the presence of ﬂexible regions, which could
correspond to the loops of the Hc-C subdomain (Fig. 1). The
rest of both spectra exhibit low intensities. Proteins mainly
devoid of a-helices, like Hc (5%) and Hc-C (2.9%) [6], give low
signals [15]. Moreover, CD spectroscopy is known to be poorly
sensitive to b-structures. Hence, for proteins with few b-
structures like Hc-C, which contains 20% of b-sheet [6], the CD
spectrum is weak.
Overall, these results indicate the presence of b-structures in
all three proteins, although positive and negative contributions
from other secondary structure motifs or aromatic residues
cannot be excluded.
The CD spectra of Hc and Hc-C exhibited positive bands at
233 and 228 nm, respectively (Fig. 3A and B). These bands
could arise from rotational constraints on aromatic side
chains, as described for other proteins [16–19]. At these
wavelengths, such signals may imply diﬀerent transitions from
the aromatic rings [20]: the La transition of tyrosine and the Bb
band of Trp, located at 229 and 225 nm, respectively, are good
candidates. These positive bands most likely reﬂected the chi-
ral activity of the same aromatic residue(s). The maximum
wavelength of the Hc band was probably red-shifted as com-
pared to the one of Hc-C (Fig. 3B) due to the relatively more
elevated dichroic contribution in this region of the Hc poly-
peptide backbone to the resulting signal as compared to Hc-C
[16]. Together, the results suggest that Hc-C preserved this
element of tertiary structure when isolated or within the entire
Hc domain.
The near-UV CD spectrum of the Hc domain (Fig. 3C)
showed two weak negative bands at 264 and 270 nm, a broad
and strong signal between 280 and 310 nm, including two
negative bands at 290 and 297 nm with a positive band at 293
nm in-between. The ﬁrst two ﬁne bands may arise from vib-
ronic transitions of phenylalanines. The ﬁne bands above 290
nm could be assigned to Lb transitions of Trps [20]. The near-
UV CD spectrum of the Hc-N subdomain displayed similar
ﬁne bands, but the strong negative signal ranging from 280 to
310 nm in the CD spectrum of Hc was not observed. The CD
spectrum of Hc-C was essentially composed of two features: a
broad negative band between 260 and 290 nm and a positive
signal at 294 nm. These results indicate that several aromatic
side chains in the isolated subdomains were buried in chiral
environments, providing direct evidence that these isolated
subdomains had a tertiary structure.
Nevertheless, the sum of the Hc-N and Hc-C near-UV CD
spectra did not reﬂect the spectrum of Hc (Fig. 3C and D).
Although the ﬁne bands above 290 nm seemed preserved, the
strong negative signal between 280 and 310 nm lacked. Such
signal was unusually intense and probably involved the par-
ticipation of several Trps with high chiral activities. We suggest
that this band could arise from the tight packing of some or allﬁve Trps conﬁned in the interfacial region connecting Hc-N
and Hc-C (Fig. 1).
The ﬂuorescence of Trps is sensitive to their environment.
The three proteins had similar maximum wavelength emissions
(kmax), although the kmax of Hc-C appeared slightly red-shifted.
(Table 1). These values suggest that the Trps share a similar
environment within the isolated subdomains or within the
whole domain. However, the sum of the ﬂuorescence intensi-
ties of both subdomains did not reﬂect the ﬂuorescence in-
tensity of the entire domain. A partial exposure to the solvent
of the Trps of both subdomains could explain this discrepancy.
In particular, the exposure of the Trps buried in the hydro-
phobic interfacial region of the two subdomains (Fig. 1) could
explain this loss of ﬂuorescence intensity.
The thermal unfolding of a protein allows to investigate its
stability. The results in Fig. 4 show that the kmax of the three
proteins remained at the same value between 10 and 50 C. The
three proteins were stable at least 10 C above 37 C, the
temperature of intraperitoneal injection. Thus, the proteins
were accumulated in a thermodynamic state, which most likely
corresponded to their respective native states.
Overall, CD and ﬂuorescence data strongly suggest that Hc-
N and Hc-C were folded and exhibited the same structural
features whether isolated or within Hc. The diﬀerences be-
tween both subdomains and the whole Hc domain, observed in
the near-UV region of the CD spectra and for ﬂuorescence
intensities, may be ascribed to the Trps embedded in the apolar
interfacial region of Hc, connecting Hc-N and Hc-C. When the
subdomains are isolated, the Trps located at the connecting
interface (Fig. 1) may enhance their dynamics due to the loss of
tight packing and become partially exposed to the solvent,
M. Tavallaie et al. / FEBS Letters 572 (2004) 299–306 303diminishing both near-UV CD signals and Trp ﬂuorescence
intensities, respectively.3.3. Serum antibody ELISA titers
The immunoglobulin titers of sera from mice vaccinated
against Hc, Hc-N and Hc-C were measured by ELISA. Blood
samples were taken 17 days after the last vaccination. Total
immunoglobulin ELISA titers of mice immunized with Hc-C
were slightly but not signiﬁcantly higher than those of mice in-
oculated with Hc or Hc-N (Fig. 5A–C). Speciﬁc IgG against Hc
detected by ELISA were signiﬁcantly higher in mouse immu-
nizedwithHc-C compared to immunizationswithHcandHc-N,
which induced similar IgG levels (Fig. 5D–F). Speciﬁc Hc IgM
were not signiﬁcantly detected in any experiment, even at 1/50
serum dilution. Double and triple immunizations provided an
ELISA response in total immunoglobulins and IgG signiﬁcantly
higher than the single immunization.3.4. Protection of mice against challenge with BoNT/A
Single and multiple immunizations have been performed in
mice and protection has been monitored by challenge with
BoNT/A (103 MLD50/mouse) by intraperitoneal injections. A
single immunization with Hc induced a protection level, whichTotal immunoglobulins
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Fig. 5. ELISA titers of sera from mice immunized with Hc, Hc-N and Hc-C
dilutions of sera starting at 1:200 were used. Mean values and standard erro
immunized mice.increased with increasing vaccination doses from 30% with 100
ng/animal to 90% with 5 lg/dose. Full protection was achieved
with 10 lg of Hc. The protection levels with the various
amounts of the whole Hc domain (Table 2) were similar to
those already reported by Byrne and Smith [10]. In single and
double immunization experiments, equivalent protein
amounts of Hc-N and Hc-C did not provide any signiﬁcant
protection in mice. The highest tested amounts of Hc-N and
Hc-C (10 lg) did not give any protection, whereas the same
dose of Hc protected 100% of the mice. In a triple immuni-
zation experiment with 10 lg of recombinant protein, Hc and
Hc-C yielded a 100% protection, whereas the same amount of
Hc-N only protected 30% of the mice using a challenge of 105
MLD50/animal. These results indicate that the individual
subdomains induced a poor protection compared to the whole
Hc domain.
Since both Hc-N and Hc-C seemed required to elicit a full
protection of the animals, we tested whether the simultaneous
injection of the two isolated subdomains induced the same
level of protection as the whole Hc. Single immunizations
with Hc-N plus Hc-C (2.5 and 5 lg/mouse) did not elicit
any protection, whereas equivalent amounts of Hc (5 and 10
lg/mouse) induced 90% and 100% protection, respectively
(Table 2).IgG
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Table 2
Eﬃcacy of Hc, Hc-N, and Hc-C vaccines in mice
Antigen Protein amount (lg) No. of survivors/Total mice (%)
Single immunization, challenge 20 days later with 103 MLD/mouse
Hc 0.1 6/20 (30%)
0.3 4/6 (66%)
1 17/26 (65%)
5 9/10 (90%)
10 10/10 (100%)
Hc-N 0.1 0/20
0.3 0/6
1 1/26 (3.8%)
5 0/10
10 0/10
Hc-C 0.1 0/20
0.3 0/6
1 3/26 (11%)
5 0/10
10 0/10
Hc-N+Hc-C 2.5+ 2.5 0/10
5+5 0/10
Double immunization with 2 weeks interval and challenge with 103 MLD/mouse 20 days later
Hc 0.3 5/5
1 5/5
Hc-N 0.3 0/5
1 0/5
Hc-C 0.3 0/5
1 0/5
Triple immunization with 2 weeks interval and challenge with 105 MLD/mice 20 days later
Hc 10 10/10
Hc-N 10 3/10
Hc-C 10 10/10
Mice were injected with Hc, Hc-N, Hc-C or a combination of Hc-N and Hc-C in single (A), double (B) or triple (C) immunizations with Alugel, and
challenged with BoNT/A as indicated. The numbers of survivors from the total number of challenged mice are recorded.
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Like for tetanus, the protection against botulism acquired by
vaccination results from neutralizing anti-toxin antibodies in
the blood circulation [21]. Therefore, neutralizing antibodies
against BoNT/A have been assayed in sera of immunized mice,
using the protection test in mice as described in Section 2.
Neutralizing antibody titers increased with the number of
immunizations and the highest levels were obtained after a
triple immunization (Table 3). In agreement with the protec-
tion assays against a BoNT/A challenge (Table 2), mice im-
munized with the whole Hc showed the highest levels of
neutralizing antibodies in the serum, whereas immunizations
with Hc-N induced the lowest levels (Table 3). Hc-C was more
potent than Hc-N to induce neutralizing antibodies. Similar
results were obtained in rabbits immunized three times (T0,
T0 + 4 weeks and T0 + 6 weeks) with 100 lg of recombinantTable 3
Serum neutralizing antibody titers of mice immunized once, twice or
three times with 1 lg of Hc, Hc-N or Hc-C. Neutralizing titers, ex-
pressed as the inverses of the highest serum dilutions which neutralized
10 MLD of BoNT/A, are the mean of ﬁve mice
Antigen Single
immunization
Double
immunization
Triple
immunization
Hc 20 640 8000
Hc-N 0 20 320
Hc-C 0 160 1280protein associated to Freund’s adjuvant at each injection.
Titers of neutralizing antibodies against BoNT/A were 20 000
in the serum of rabbit immunized with Hc, 200 with Hc-N
immunization, and 2000 with Hc-C immunization.4. Discussion
We have investigated the possibility to use fragments of the
BoNT/A Hc domain to generate recombinant vaccines or an-
tigens for immunizing animals for the production of protective
antibodies. Our results show that Hc and its two subdomains,
Hc-N and Hc-C can be eﬃciently produced as His-tag fusion
proteins in E. coli. CD and ﬂuorescence studies have shown
that the three proteins were folded and stable. The proteins
elicited serum immune responses in mice as tested by ELISA.
The levels of antibodies determined by ELISA increased ac-
cording to the number of immunizations, but no relevant
diﬀerence in total immunoglobulins was observed in mice im-
munized with Hc or the two subdomains. Hc-C seemed to be a
better immunogen than Hc and Hc-N to induce an IgG re-
sponse as detected by ELISA. ELISA method measures anti-
bodies that recognize various epitopes on the antigen molecule
but is not predictive of the protection induced against the
toxin. Indeed, only the whole Hc domain conferred a high
protection in mice against a challenge with BoNT/A, whereas
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was found to protect mice only when a triple immunization
procedure (10 lg/mouse) was applied, whereas the same
amount of Hc was fully protective after a single injection. Hc-
N did not induce any signiﬁcant protection. Levels of neu-
tralizing antibodies in sera of immunized mice corroborated
the challenge experiments. Mice immunized with Hc showed
the highest serum neutralizing titers. Hc-C was more potent
than Hc-N and less eﬃcient than the whole Hc to induce
neutralizing antibodies. These results are in agreement with
previous epitope mapping studies, suggesting that Hc-C con-
tains the major epitopes involved in protection [11,12,22–25].
However, our results show that Hc-C per se was not suﬃcient,
the whole Hc domain was required to induce a high level of
protection in mice.
The neutralization of the initial binding of the toxin to cells
is the most eﬃcient way of protection. The neuronal receptor
of clostridial neurotoxins has not been fully elucidated. It is
supposed to correspond to sialo-gangliosides and a protein
[26]. The protein receptor has been characterized for BoNT/B
and BoNT/G only, which is synaptotagmin I and II, but not
for the other BoN/T nor for TeTx [27,28]. In TeTx, which is
structurally related to BoNT, it has been reported that Hc-C is
necessary and suﬃcient to bind to the neuronal cell surface and
to interact with the dual receptor consisting of polysialogan-
gliosides and a 15 kDa putative protein receptor, whereas Hc-
N does not show any speciﬁc binding [29]. Cocrystal structure
with synthetic ganglioside showed that TeTx Hc-C contains
multiple ganglioside binding sites [30]. TeTx binds simulta-
neously two ganglioside molecules [31], whereas BoNT/A and
BoNT/B only contain one ganglioside binding site [32]. In
BoNT/B, the ganglioside binding site was mapped in Hc-C
[33]. A similar binding structure is probably conserved in
BoNT/A (residues 1266–1272) [30]. For all the clostridial
neurotoxins, the binding site(s) to the protein receptor moiety
has not been mapped. The multiple interactions between the
neurotoxin and the dual receptor, ganglioside and protein,
account for the ﬁndings that single monoclonal antibodies
weakly neutralize BoNT/A, whereas an association of three
monoclonal antibodies against Hc is eﬃciently protective
[25,34]. The fact that the whole Hc, but not isolated Hc-N or
Hc-C, induced eﬃcient protection may suggest that both
subdomains are involved in the receptor binding.
Surprisingly, we found that the co-injection of Hc-N and
Hc-C was less eﬃcient than the injection of the whole Hc
domain to generate protective antibodies. Thus, the native
connection of Hc-N to Hc-C is required to induce high pro-
tection in mice. This could suggest that the binding site for the
highest aﬃnity receptor involves both subdomains and may be
located near the interfacial region of the subdomains. Re-
cently, Atassi and Dolimbek have shown that protective an-
tibody epitopes of BoNT/A H-chain are mainly located in the
Hc subdomains, most of them belonging to the interfacial re-
gion [35]. In the whole Hc domain, Hc-N and Hc-C are tightly
packed together, as shown by the crystal structure [6] (Fig. 1)
and by the spectroscopy results presented here (Fig. 3D and
Table 1). A high ﬂuorescence intensity and a strong near-UV
CD signal showed that Trps are buried in the structure and
involved in a highly constrained region in the Hc domain,
which is not the case in the isolated subdomains. The separa-
tion of the subdomains leading to the exposure to the solvent
of the Trps located in the interfacial region may explain thedecrease of the ﬂuorescence intensity and of the CD signal.
Therefore, the isolated subdomains could loose their native
structure and, consequently, their conformational epitopes, in
the vicinity of the interfacial region due to the absence of
stabilizing tertiary interaction between both subdomains. This
could explain the requirement for the whole folded Hc domain
to induce a high level of protection in mice as discussed above.
Alternatively, all potential discontinuous epitopes overlapping
Hc-N and Hc-C are lost when the subdomains are isolated,
which may explain the incapacity of isolated subdomains to
protect mice. Indeed, it has been shown using monoclonal
antibody that discontinuous epitopes are involved in protec-
tion [34].
In conclusion, we show that the whole structure of BoNT/A-
Hc is necessary to eﬃciently stimulate a protective immuno-
logical response, since single immunization with Hc elicited
90–100% protection level, and equivalent amounts of Hc-N,
Hc-C or Hc-N plus Hc-C did not induce any protection.
Therefore, no smaller recombinant fragment than Hc can be
used as a vaccine candidate or antigen for the production of
protective antibodies against BoNT/A. Conformational epi-
topes from Hc are lost when cleaved in its two subdomains.
These epitopes seem critical for the protective immunological
response. Since the protective response is essentially due to
antibodies, which prevent binding of the toxin to its cellular
receptor, the site of interaction with the receptor is likely lo-
cated in the vicinity of the interfacial region of Hc-N and Hc-
C. These data provide additional insights to design eﬃcient
recombinant vaccine candidates and potent tools to generate
neutralizing polyclonal or monoclonal antibodies against
botulinum neurotoxins.Acknowledgements: This work was supported by DRET contract
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